{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:10:47Z","timestamp":1787163047061,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21372050"],"award-info":[{"award-number":["21372050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Shanghai Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["13ZR1402200"],"award-info":[{"award-number":["13ZR1402200"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.bmcl.2018.10.010","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T13:31:00Z","timestamp":1539091860000},"page":"3491-3495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Design and synthesis of a novel series of non-nucleoside HIV-1 inhibitors bearing pyrimidine and N-substituted aromatic piperazine"],"prefix":"10.1016","volume":"28","author":[{"given":"KaiJun","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YaLi","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"De Clercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Pannecouque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2018.10.010_b0005","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jhep.2005.11.021","article-title":"Update on HAART in HIV","volume":"44","author":"Yeni","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmcl.2018.10.010_b0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2009.09.014","article-title":"Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine","volume":"85","author":"Cihlar","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bmcl.2018.10.010_b0015","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1126\/science.1206399","article-title":"Turning the tide against HIV","volume":"333","author":"Shattock","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2018.10.010_b0020","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2174\/092986708784221467","article-title":"The current status of the NNRTI family of antiretrovirals used in the HAART regime against HIV infection","volume":"15","author":"Martins","year":"2008","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmcl.2018.10.010_b0025","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1021\/jm200990c","article-title":"Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms","volume":"55","author":"Li","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2018.10.010_b0030","first-page":"132","article-title":"Special contribution 2017 update of the drug resistance mutations in HIV-1","volume":"24","author":"G\u00fcnthard","year":"2017","journal-title":"Topics in Antiviral Med"},{"key":"10.1016\/j.bmcl.2018.10.010_b0035","doi-asserted-by":"crossref","DOI":"10.1002\/med.20241","article-title":"HIV\u20101 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design","volume":"33","author":"Zhan","year":"2013","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmcl.2018.10.010_b0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.antiviral.2009.09.008","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009)","volume":"85","author":"de B\u00e9thune","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bmcl.2018.10.010_b0045","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00126839-200405050-00001","article-title":"Correlations between factors determining the pharmacokinetics and antiviral activity of HIV-1 non-nucleoside reverse transcriptase inhibitors of the diaryltriazine and diarylpyrimidine classes of compounds","volume":"5","author":"Lewi","year":"2004","journal-title":"Drugs R&D"},{"key":"10.1016\/j.bmcl.2018.10.010_b0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1075-8593(06)05006-4","article-title":"The medicinal chemistry of the DATA and DAPY series of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs)","volume":"5","author":"Heeres","year":"2007","journal-title":"Adv Antiviral Drug Des"},{"key":"10.1016\/j.bmcl.2018.10.010_b0055","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/AAC.00986-09","article-title":"TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1","volume":"54","author":"Azijn","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2018.10.010_b0060","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.clinthera.2009.04.020","article-title":"Etravirine: A second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV","volume":"31","author":"Schiller","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.bmcl.2018.10.010_b0065","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejmech.2013.04.052","article-title":"Molecular design, synthesis and biological evaluation of BP- O -DAPY and O -DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors","volume":"65","author":"Yang","year":"2013","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2018.10.010_b0070","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/cmdc.200900212","article-title":"Design, Synthesis, and SAR of Naphthyl-Substituted Diarylpyrimidines as Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase","volume":"4","author":"Liang","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2018.10.010_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2015.04.050","article-title":"Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors","volume":"97","author":"Wan","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2018.10.010_b0080","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.ejmech.2018.01.016","article-title":"Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1","volume":"145","author":"Jin","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2018.10.010_b0085","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/jps.22242","article-title":"Physicochemical properties of the amorphous drug, cast films, and spray dried powders to predict formulation probability of success for solid dispersions: etravirine","volume":"100","author":"Weuts","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bmcl.2018.10.010_b0090","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1365-2125.2008.03214.x","article-title":"A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV\u2013negative volunteers","volume":"66","author":"Sch\u00f6llergy\u00fcre","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bmcl.2018.10.010_b0095","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.37.5.1127","article-title":"U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication","volume":"37","author":"Dueweke","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2018.10.010_b0100","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1021\/jm070811e","article-title":"Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains","volume":"50","author":"Mai","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2018.10.010_b0105","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejmech.2014.09.054","article-title":"Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization","volume":"87","author":"Liu","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2018.10.010_b0110","doi-asserted-by":"crossref","first-page":"7219","DOI":"10.1021\/jm3007678","article-title":"Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates","volume":"55","author":"Sun","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2018.10.010_b0115","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1016\/j.tet.2011.04.093","article-title":"In situ generation of palladium nanoparticles: ligand-free palladium catalyzed ultrafast Suzuki-Miyaura cross-coupling reaction in aqueous phase at room temperature","volume":"67","author":"Du","year":"2011","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bmcl.2018.10.010_b0120","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1016\/j.bmc.2015.06.048","article-title":"Hybrid chemistry. Part 4: Discovery of etravirine\u2013VRX-480773 hybrids as potent HIV-1 non-nucleoside reverse transcriptase inhibitors","volume":"23","author":"Wan","year":"2015","journal-title":"Bioorg Med Chem"},{"issue":"17","key":"10.1016\/j.bmcl.2018.10.010_b0125","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1021\/acs.jmedchem.6b00738","article-title":"Design, synthesis and evaluation of thiophene[3,2-d]pyrimidine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors with significantly improved drug resistance profiles","volume":"59","author":"Kang","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2018.10.010_b0130","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1021\/jm1002233","article-title":"Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design","volume":"53","author":"Lansdon","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2018.10.010_b0135","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10822-007-9114-2","article-title":"Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search","volume":"21","author":"Jain","year":"2007","journal-title":"J Comput Aided Mol Des"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X1830800X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X1830800X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:25:51Z","timestamp":1760772351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X1830800X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":27,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0960894X1830800X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2018.10.010","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of a novel series of non-nucleoside HIV-1 inhibitors bearing pyrimidine and N-substituted aromatic piperazine","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2018.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}